GlaxoSmithKline PLC (GSK) News

GlaxoSmithKline PLC (GSK): $43.75

0.22 (+0.51%)

POWR Rating

Component Grades













Filter GSK News Items

GSK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GSK News Highlights

  • GSK's 30 day story count now stands at 32.
  • Over the past 24 days, the trend for GSK's stories per day has been choppy and unclear. It has oscillated between 1 and 9.
  • VIR, DRUG and MRNA are the most mentioned tickers in articles about GSK.

Latest GSK News From Around the Web

Below are the latest news stories about Glaxosmithkline Plc that investors may wish to consider to help them evaluate GSK as an investment opportunity.

GlaxoSmithKline: Set to Make Investors Very Happy

After listening to Emma Walmsley, the CEO of GlaxoSmithKline (GSK), at the J.P. Morgan Healthcare Conference on January 11, 2022, I am confident that she and her management team have a plan to drive shareholder value for years to come.  First and foremost, what I like most about Walmsley’s time as CEO is that she has replaced over 85% of the top 125 leaders at GSK. She has also brought in outside perspectives by replacing over 30% of those top 125 leaders with people from outside the organization. Walmsley has also stated that she intends to split the company into two by the middle of this year.

Tim O'Rourke on TipRanks | February 25, 2022

VIR Q4 Earnings Beat on Higher Revenues From Covid Treatment

VIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients.

Yahoo | February 25, 2022

CDC expected to loosen COVID face-mask advice on Friday, and Canada authorizes first plant-based vaccine

The Centers for Disease Control and Prevention is expected to announce later Friday a loosening of federal face-mask requirements that will mean that most Americans will no longer be advised to wear them in indoor spaces.

Yahoo | February 25, 2022

Allscripts' (MDRX) Q4 Earnings Beat Estimates, Margins Up

Allscripts' (MDRX) robust Q4 results demonstrate strength in both segments.

Yahoo | February 25, 2022

Pharma Stock Roundup: GSK, SNY Face Pipeline Setbacks, AZN Cancer Study Meets Goals

Glaxo (GSK) and Sanofi (SNY) announce pipeline setbacks. AstraZeneca's (AZN) HER2-low metastatic breast cancer study on Enhertu succeeds.

Yahoo | February 25, 2022

Chemed (CHE) Q4 Earnings Surpass Estimates, Revenues Miss

Chemed (CHE) reports better-than-expected earnings for the fourth quarter, with a robust performance by the Roto-Rooter arm driving the top line.

Yahoo | February 25, 2022

Teleflex (TFX) Q4 Earnings & Revenues Top Estimates, Margins Up

Strong segmental performance in the domestic and international markets is driving Teleflex's (TFX) fourth-quarter top line.

Yahoo | February 25, 2022

Nevro's (NVRO) Q4 Earnings in Line, Revenues Beat Estimates

Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q4 due to soft geographical performances.

Yahoo | February 24, 2022

Avanos Medical (AVNS) Q4 Earnings, Revenues Top Estimates

Avanos Medical's (AVNS) fourth-quarter 2021 results gain from strength in the chronic care segment.

Yahoo | February 24, 2022

UPDATE 3-Canada approves Medicago's plant-based COVID-19 vaccine for adults

Medicago's vaccine on Thursday became the world's first plant-based shot approved against COVID-19 after Health Canada cleared it for use in adults. The two-dose vaccine, which uses an adjuvant from GlaxoSmithKline to boost immune response, is the sixth COVID-19 shot to receive regulatory clearance in the country. The Quebec-based privately held company has an agreement to supply up to 76 million doses of the vaccine to the Canadian government.

Yahoo | February 24, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.542 seconds.